Get the knowledge

She is 41. She still has her periods — mostly. She runs her life competently: the career, the children, the relationship, the mental load that never fully switches off. She is not someone who “does” anxiety.

And yet.

The two weeks before her period have started to feel like standing on sand that keeps shifting. She snaps at her children for small things and then weeps with guilt in the car. She wakes at 3am certain something terrible is about to happen, with no idea what. A difficult email from a colleague sends her spiralling for hours. Her heart races at random — not dramatically, just enough to notice. She has an internal buzzing she cannot describe to anyone. She is exhausted but cannot settle.

Her GP offers antidepressants. Her blood tests come back normal. Her therapist suggests mindfulness. Everyone is kind. Nobody mentions perimenopause.

Nobody mentions it because she is still cycling. And a persistent myth — in medicine as much as in culture — holds that perimenopause means menopause is close, hot flushes have started, periods have stopped. None of this is true. Early perimenopause can begin in the late 30s or early 40s, with cycles still regular, blood tests still “normal,” and anxiety as the first and most disabling symptom.

This article is for the women who are in that gap — between who they were at 35 and what is actually happening in their hormonal landscape. The anxiety they are experiencing has a mechanism. It has a name. And it is not who they are becoming.

How Common Is Perimenopause Anxiety?

Anxiety is one of the most prevalent and least-recognised symptoms of the perimenopause transition. Studies have found that women in perimenopause are significantly more likely to develop high anxiety symptoms than premenopausal women, with odds ratios of 1.56–1.61 even when controlling for life events, financial strain, and vasomotor symptoms — suggesting the hormonal component is independent of external stress. Global data project that the burden of anxiety disorders in perimenopausal women will rise to 1,180 per 100,000 by 2035, a 40% increase on 2021 levels.

The symptom most associated with this transition — across large survey data — is not the hot flush. It is “feeling like I can’t calm down on the inside.”

That phrase is a clinical fingerprint. It describes what happens when the brain loses its primary calming system.

The Mechanism: A Ratio Problem between Oestrogen and Progesterone

Perimenopause anxiety is not simply caused by low progesterone. It is caused by a hormonal ratio problem — and understanding both sides of that ratio is what separates a complete clinical picture from a partial one.

Side one: the brake is removed. As perimenopause begins, ovarian fibrosis causes some cycles to occur without ovulation. Without ovulation, progesterone is not produced. Without progesterone, a critically important brain metabolite called allopregnanolone disappears — and with it, the brain loses the signal that keeps GABA-A receptors — the nervous system’s primary calming switch — active. The inhibitory brake is gone.

Side two: the accelerator is pressed. At the same time, oestrogen does not decline proportionally. In early perimenopause, oestrogen is erratic — it spikes to abnormally high levels before crashing, driven by the chaotic follicle recruitment that characterises this phase. These surges of unchecked oestrogen overstimulate glutamate, the brain’s primary excitatory neurotransmitter, and sensitise the stress response axis. With no progesterone present to counterbalance it, oestrogen’s excitatory effects run unopposed.

The result is a nervous system with the excitatory accelerator pressed and the inhibitory brake missing simultaneously. This is why perimenopause anxiety has the specific quality it does — not simply worried thoughts, but a physiological state of hyperarousal that women consistently describe as “I can’t calm down on the inside.”

The full framework is explained on The Progesterone Shift →

The GABA-A Connection: Your Brain’s Natural Calming Brake

To understand why progesterone loss causes anxiety, you need to understand one neurochemical relationship that most GPs have never mentioned to their patients.

GABA (gamma-aminobutyric acid) is the brain’s primary inhibitory neurotransmitter. If the nervous system is an engine running constantly, GABA is the brake. It slows neural firing, reduces reactivity, promotes emotional regulation, and creates the felt sense of being able to cope. When GABA signalling is working well, small provocations stay small. Stressful things can be processed and released. Sleep comes.

GABA-A receptors are the specific receptor sites that GABA acts on. And these receptors are not activated by GABA alone — they are powerfully amplified by a molecule called allopregnanolone.

Allopregnanolone is a neurosteroid — a steroid that acts directly in the brain — and it is made from progesterone. Specifically, it is the 3α-reduced metabolite of progesterone, and it functions as a positive allosteric modulator of GABA-A receptors. In plain language: it amplifies the effect of GABA at these receptor sites, turning up the brain’s inhibitory signal and providing the nervous system with a natural, endogenous calming mechanism.

This is not a minor effect. Research consistently shows that allopregnanolone plays a central role in emotional regulation, stress response, and anxiety, with its decline implicated in premenstrual dysphoric disorder, postpartum depression, and perimenopausal mood disruption. When allopregnanolone is present and stable, the nervous system has its brake. When it drops — as it does when progesterone is not produced after an anovulatory cycle — the brake is released.

What happens to the brain when GABA-A receptors lose allopregnanolone stimulation:

• GABA signalling is no longer amplified — the inhibitory system is weakened
• Neural excitability increases — the brain fires more readily
• The stress response axis (HPA axis) loses GABAergic regulation
• Small stressors generate disproportionate responses
• Emotional regulation becomes effortful rather than automatic
• Sleep architecture deteriorates — the nervous system cannot “switch off”
• A background sense of internal tension or restlessness develops — the “internal buzzing” women frequently describe

This is perimenopause anxiety. Not a personality change. Not depression. Not burnout, though it may coexist with all of these. It is the nervous system running without its biochemical brake.

Why the Pattern Is Cyclical

Here is the clinical key that helps women identify this as hormonal rather than psychological: the anxiety has a cyclical pattern tied to the second half of the cycle.

In a fully ovulatory cycle, progesterone rises after ovulation in the luteal phase (approximately days 14–28). This progesterone rise produces allopregnanolone, which amplifies GABA-A activity, and women typically feel more emotionally resilient and regulated in the first half of their cycle. As progesterone falls before the period, allopregnanolone drops, GABA-A stimulation decreases, and some degree of premenstrual mood shift is normal.

In early perimenopause, when ovulation is increasingly skipped, the luteal phase progesterone rise simply does not happen. There is no progesterone to convert to allopregnanolone. The GABA-A brake is not engaged at all in that second half of the cycle. And as ovulation becomes more intermittent — which is the defining biological feature of perimenopause — this GABA-A deficiency becomes longer and more frequent.

Women describe it like this: “I’m completely fine for two weeks, then I fall apart for two weeks.”

That is not a psychological pattern. That is a hormonal one. The two weeks of falling apart correspond precisely to the luteal window when progesterone should be rising but cannot, because ovulation did not occur.

As perimenopause progresses and anovulatory cycles become more frequent, the windows of GABA-A deprivation lengthen. Eventually, if the pattern is not addressed, the anxiety may become more constant — but in early perimenopause, this cyclical signature is the clearest clinical clue.

The Other Side of the Equation: What Erratic Oestrogen Does to the Brain

Most explanations of perimenopause anxiety stop at progesterone loss. But the hormonal picture of early perimenopause has two sides, and the second is just as clinically important. While progesterone is falling, oestrogen is not declining in a calm, linear way — it is spiking erratically and unpredictably, driven by the chaotic multi-follicle recruitment that the struggling ovaries are producing. These surges are not physiologically normal. They are pharmacologically high levels of oestrogen arriving without the progesterone counterbalance that would ordinarily be present.

Erratic oestrogen overstimulates the nervous system through five distinct mechanisms:

1. Glutamate Overstimulation

Oestrogen enhances the transmission and synthesis of glutamate, the brain’s primary excitatory neurotransmitter. When oestrogen levels are stable, this excitatory effect is part of normal neurological function — it supports cognition, memory, and alertness. When oestrogen spikes excessively, as it does during erratic perimenopausal cycles, it overstimulates glutamate receptors. The brain floods with excitatory signals. The subjective experience: racing thoughts, inability to settle, a pervasive sense of dread or hypervigilance that arrives before any identifiable trigger. This is not a psychological response to circumstances. It is oestrogen pressing the neurological accelerator without restraint. Research on oestrogen’s role in glutamatergic transmission has been documented in studies of synaptic plasticity and excitatory signalling, including work published by Schwarz and McCarthy (2008) in Neuropsychopharmacology and Foy et al. (PMC4769981).

2. GABA Suppression

High oestrogen, in the absence of progesterone, reduces the brain’s sensitivity to its own GABA signalling through downregulation of certain GABA-A receptor subunits. This compounds the allopregnanolone loss described above. The brake system is not simply missing its amplifier — oestrogen is actively reducing the sensitivity of the receptor it would amplify. With glutamate elevated and GABA suppressed simultaneously, the nervous system becomes locked in a state of high baseline physiological arousal. Sleep does not come easily. Calm requires effort. The “off switch” is harder to find.

3. HPA Axis Hypersensitisation

The hypothalamic-pituitary-adrenal (HPA) axis governs the stress response. Erratic, high oestrogen over-sensitises the HPA axis, making it hyper-reactive to incoming stimuli. Minor daily stressors that would previously have been processed without difficulty now trigger exaggerated cortisol and adrenaline responses. This is the clinical basis for the experience many women describe as “I’ve become someone who can’t handle things” — the threshold for threat has not changed psychologically, but the neurological reactivity has changed hormonally. Physical anxiety symptoms — chest tightness, racing heart, the sudden feeling that something is wrong — can precede any conscious anxious thought, because the HPA axis has already fired before the cortex has had time to form a narrative.

4. Serotonin and Dopamine Volatility

Oestrogen heavily influences the synthesis, degradation, and transport of both serotonin and dopamine. When oestrogen is stable, this relationship supports mood. When it swings from extreme highs to rapid crashes — as it does in early perimenopause — serotonin receptor sensitivity becomes volatile. The clinical result: sudden, unprovoked mood crashes, acute irritability, and episodes that feel like panic but arrive without warning. This is also why SSRIs often produce incomplete results for perimenopausal anxiety — they address the serotonin instability downstream without touching the oestrogen volatility driving it upstream. The serotonin system is being disrupted by hormonal chaos that the antidepressant cannot see.

5. Sleep Architecture Disruption

High and erratic oestrogen is directly disruptive to REM and deep sleep cycles. It destabilises the brain’s internal thermostat, triggers nocturnal adrenaline activity, and can drive night sweats even in early perimenopause when daytime vasomotor symptoms have not yet appeared. Chronic sleep disruption then degrades prefrontal cortex function — the brain’s primary emotional regulation centre — leaving women markedly more vulnerable to morning anxiety and daytime emotional volatility. This creates a self-sustaining cycle: oestrogen disrupts sleep, poor sleep impairs emotional regulation, impaired emotional regulation amplifies the subjective experience of anxiety, anxiety further disrupts sleep. The clinical picture that emerges from these five mechanisms is not psychiatric. It is neurological and hormonal. And it is the reason why addressing only the progesterone side — without also addressing oestrogen clearance and oestrogen:progesterone ratio — leaves half the mechanism untouched

The Four Amplifiers

Beyond the core ratio problem, four additional biological factors deepen the hormonal imbalance and make the anxiety worse.

1. The Insulin–Oestrogen Loop

When insulin is chronically elevated — through refined carbohydrates, blood sugar dysregulation, or insulin resistance — it drives the ovaries to produce androgens (testosterone-like hormones). These androgens are then converted by an enzyme called aromatase into oestrogen. The result: more oestrogen in circulation, relative to the already-depleted progesterone.

This matters because anxiety in early perimenopause is not just about low progesterone in absolute terms — it is about the ratio of oestrogen to progesterone. With oestrogen rising and progesterone falling, the hormonal environment becomes oestrogen-dominant. This compounds the GABA-A deficiency and drives the full cluster of symptoms associated with oestrogen dominance — anxiety, breast tenderness, bloating, heavy periods, and insomnia.

Every time blood sugar spikes, the insulin–oestrogen loop adds fuel to this imbalance.

2. Poor Oestrogen Clearance via Liver and Gut

The liver is responsible for packaging used oestrogen for excretion. It conjugates oestrogen molecules, binding them so they can be excreted in bile. But in the gut, bacteria with high beta-glucuronidase activity can deconjugate these oestrogen molecules — essentially unpackaging them and allowing them to be reabsorbed into circulation.

The collection of gut bacteria involved in this process is called the estrobolome. When the estrobolome is dysbiotic — skewed toward high beta-glucuronidase activity through poor diet, antibiotic use, stress, or gut dysbiosis — oestrogen that should be cleared gets recirculated. Research confirms that gut microbial beta-glucuronidase enzymes play a central role in reactivating oestrogens and returning them to systemic circulation.

The practical result for women in early perimenopause: even without additional oestrogen coming in, poor clearance means the oestrogen that is present stays present for longer — compounding oestrogen dominance and keeping the oestrogen:progesterone ratio skewed.

3. Chronic Stress Suppresses Progesterone via the Brain

This is the most vicious of the four amplifiers, because it creates a self-reinforcing loop between stress and hormonal depletion.

You may have heard the term “pregnenolone steal” — the idea that cortisol and progesterone compete for the same precursor and stress diverts that raw material away from progesterone. It circulates widely in popular wellness content, but it is not supported by endocrinology. The adrenal glands and ovaries operate as entirely separate steroidogenic systems with their own substrate pools.

What chronic stress actually does is more precise, and more important to understand: chronic stress → elevated cortisol → cortisol signals the hypothalamus to suppress GnRH (gonadotropin-releasing hormone) → reduced LH and FSH signalling to the ovaries → follicle development is disrupted or stalled → ovulation fails, or is skipped entirely → no corpus luteum forms → no progesterone is produced.

The progesterone was not stolen. Its production line was switched off by the brain.

For a woman in early perimenopause who is already experiencing erratic ovulation, chronic stress adds a second mechanism that suppresses it further. Less ovulation means less progesterone, less allopregnanolone, and weaker GABA-A signalling — which means more anxiety — which feeds back into more cortisol — which further suppresses GnRH — deepening the deficit.

The loop is clinically important because it means that stress management is not a lifestyle suggestion — it is a direct hormonal intervention. Every practice that reduces cortisol output protects the hypothalamic signalling chain that allows ovulation — and progesterone — to occur.

4. Oestrogen’s Excitatory Effects Unopposed

In a balanced hormonal environment, progesterone acts as a counterweight to oestrogen’s effects on the nervous system. Oestrogen is not simply excitatory — its effects are complex — but one of its key actions is the upregulation of glutamate, the brain’s primary excitatory neurotransmitter, alongside some degree of GABA downregulation via certain receptor pathways.

When progesterone is present and allopregnanolone is amplifying GABA-A receptors, these excitatory tendencies are held in check. When progesterone is absent, they run unchecked. The result is a nervous system running with the excitatory accelerator pressed and the inhibitory brake missing — excitable, hyperreactive, prone to interpreting neutral events as threatening.

This is why perimenopause anxiety often has a specific quality of hypersensitivity: sounds feel louder, social interactions feel more charged, small frustrations generate outsized emotional responses. The nervous system’s threshold for “this is a problem” has been lowered biochemically, not psychologically.

How This Anxiety Is Different From Menopause Anxiety

Perimenopause anxiety and menopause anxiety are driven by different mechanisms, have different patterns, and require different approaches. This distinction matters because the clinical approach that works for one does not necessarily work for the other.

Perimenopause anxiety (this article):

• Driven by progesterone loss → allopregnanolone drop → GABA-A receptor under-stimulation
• Pattern: cyclical — worst in the 2 weeks before the period, better after bleeding begins
• Quality: internal tension, hypersensitivity, emotional overwhelm, rage, tearfulness, “wired but unable to rest”
• Still cycling; blood tests may appear “normal”

Later Perimenopause and post-menopause anxiety:

• Driven by declining oestrogen → brain energy crisis → compensatory cortisol and adrenaline surges
• Pattern: constant or unpredictable, not tied to a cycle
• Quality: fight-or-flight, panic, surges of adrenaline, heart pounding
• Periods have usually stopped or become very infrequent

If your anxiety arrives on a schedule — appearing in the two weeks before your period and lifting when it arrives — this is the perimenopause pattern. For late perimenopause and menopause anxiety, the mechanism is different: read the menopause anxiety article →

Why Antidepressants Often Fail for Perimenopause Anxiety

Up to a third of perimenopausal women are offered antidepressants for mood and anxiety symptoms — often before any hormonal investigation has taken place. This is a significant clinical problem, not because antidepressants are harmful in every case, but because they do not address the mechanism driving perimenopause anxiety.

SSRIs (selective serotonin reuptake inhibitors) work by increasing serotonin availability in synapses. They do not restore progesterone. They do not produce allopregnanolone. They do not stimulate GABA-A receptors. For a woman whose anxiety is driven by GABA-A receptor loss secondary to progesterone decline, an SSRI is the wrong tool — not because the tool is bad, but because it is addressing the wrong system.

Benzodiazepines do work on GABA-A receptors and will provide symptom relief — but they are addictive, they suppress symptoms without addressing the progesterone cause, they lose effectiveness as tolerance develops, and they do not restore the underlying hormonal architecture that is driving the problem.

Research on perimenopausal depression and anxiety increasingly supports the view that hormonal mechanisms — not serotonergic ones — underlie mood disturbance during this transition, and that addressing the hormonal landscape is the appropriate primary intervention for women in early perimenopause.

This is not an argument against psychiatry. It is an argument for matching the treatment to the mechanism.

What Makes Perimenopause Anxiety Worse

Several common habits and circumstances specifically amplify perimenopause anxiety:

Chronic stress is the most direct amplifier — via neurological suppression of GnRH, as described above. Every sustained cortisol demand suppresses the hypothalamic signalling that would otherwise trigger ovulation and progesterone production.

Refined carbohydrates and blood sugar dysregulation drive the insulin–oestrogen loop, worsening oestrogen dominance and deepening the oestrogen:progesterone imbalance.

Alcohol is particularly counterproductive — even though many women notice it temporarily dulls the anxiety. Alcohol initially boosts GABA activity (this is why it feels relaxing), but as it is metabolised, GABA activity drops sharply below baseline — causing rebound anxiety, worse sleep architecture, and increased emotional reactivity in the hours and days that follow. For women already GABA-A depleted, alcohol creates a worsening cycle.

Caffeine in high quantities raises cortisol and directly antagonises the adenosine system that promotes sleep and calm — compounding the neurological excitability that already exists.

Poor sleep drives cortisol dysregulation, worsening the hypothalamic suppression of GnRH, reducing the frequency of successful ovulation and therefore progesterone production, and shortening the recovery window the nervous system needs between stressors.

Case Study: Emma, 41

(Composite for illustration — details changed to protect privacy.)

Emma came to my practice in her early 40s. She was still cycling regularly, but had noticed over the previous year that the ten days before each period had become increasingly difficult. She described becoming “a completely different person” — catastrophic thinking, snapping at her children and partner, heart racing without cause, and unable to sleep despite utter exhaustion. She also described an internal buzzing or vibration she could not explain.

Her GP had suggested antidepressants. Her blood tests were normal. She had started therapy, which she found helpful but insufficient.

The first thing I noticed was the cyclical pattern. She was managing well in the first half of her cycle — organised, calm, resilient. The collapse was precise and predictable: day 14 onwards, every month, worsening each cycle.

We tested her correctly — ferritin (low-normal), B vitamins (marginally low), a full thyroid panel, a fasting insulin level, and — critically — progesterone timed to the mid-luteal phase, not at a random point in the cycle. Her mid-luteal progesterone was low, confirming that even when she appeared to be cycling normally, she was not consistently ovulating.

The protocol addressed the root cause:

• Stress reduction practices to quiet the cortisol-driven hypothalamic suppression of GnRH and protect progesterone production
• Blood sugar stabilisation — removing refined carbohydrates and supporting insulin sensitivity to break the insulin–oestrogen loop
• Liver and gut support to improve oestrogen clearance and reduce recirculation
• Magnesium glycinate — a key cofactor for GABA-A receptor function
• Vitamin B6 — an essential cofactor for progesterone synthesis and neurotransmitter production
• Targeted nutrient support to address the ferritin and B vitamin gaps

Within two cycles, Emma noticed the luteal window narrowing — the 10 bad days became 6, then 4. The intensity diminished. The catastrophic thinking became easier to observe and disengage from. Sleep improved.

“I used to dread the second half of every month,” she told me. “Now I can feel it coming but it doesn’t take me over. I feel like I can cope again.”

She did not start antidepressants. She did not need them — because the mechanism driving her symptoms was not serotonergic. It was hormonal. And when the hormonal root cause was addressed, her nervous system recovered its natural brake.

The Protocol Addresses the Root Cause

The goal is not to suppress perimenopause anxiety. The goal is to restore the conditions under which the brain can produce its own calm.

That means: supporting ovulation where possible, to restore progesterone production. Quieting the cortisol burden that suppresses the hypothalamic signals driving ovulation. Lowering insulin to reduce the oestrogen load. Clearing oestrogen efficiently through the liver and gut. Replenishing the cofactors — magnesium, B6, B vitamins — that the body needs to produce progesterone and support GABA-A function.

When the conditions are right, the brain’s own calming system — the allopregnanolone–GABA-A axis — can begin to restore itself.

The full Progesterone Shift protocol is explained here: The Progesterone Shift →

A Different Ending

The anxiety you feel in the second half of your cycle is not who you are becoming. It is not a sign that you are fundamentally anxious, or depressed, or struggling to cope. It is a neurochemical signal — your brain running without the calming brake that progesterone used to reliably provide.

You are not broken. You are not entering a permanent decline. You are experiencing a specific, mechanistic, addressable shift in the hormonal environment that regulates your nervous system.

When that environment is restored — when progesterone production is supported, the cortisol burden on the hypothalamus is reduced, oestrogen is cleared efficiently, and the GABA-A system has what it needs to function — the brake comes back. The anxiety that felt like you becomes, again, something that visits rather than something that stays.

Is The Progesterone Shift Driving Your Anxiety?

If the pattern in this article sounds familiar — anxiety that arrives on schedule in the second half of your cycle, emotional overwhelm that feels disproportionate, an internal tension you cannot explain to anyone — it may be time to look at what is actually happening in your hormonal landscape.

Book a consultation with Sandra →

References

1. Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiology of Stress. 2020;12:100213. doi:10.1016/j.ynstr.2020.100213
2. McEvoy KM, Osborne LM. Allopregnanolone and reproductive psychiatry: an overview. International Review of Psychiatry. 2019;31(3):237–244. doi:10.1080/09540261.2018.1553775
3. Kajdy A, Rogowski A, Dmoch-Gajzlerska E, et al. Progesterone and its metabolites play a beneficial role in affect regulation in the female brain. Pharmaceuticals. 2023;16(4):520. doi:10.3390/ph16040520
4. Lovick TA. Estrous cycle and stress: influence of progesterone on the female brain. Brazilian Journal of Medical and Biological Research. 2012;45(4):314–320. doi:10.1590/S0100-879X2012007500044
5. Locci A, Pinna G. Neurosteroid biosynthesis down-regulation and changes in GABAA receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment. British Journal of Pharmacology. 2017;174(19):3226–3241. doi:10.1111/bph.13843
6. Prairie BA, Clark C, Stika CS, et al. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. American Journal of Psychiatry. 2015;172(3):227–236. doi:10.1176/appi.ajp.2014.14070918
7. Wirth MM. Beyond the HPA axis: progesterone-derived neuroactive steroids in human stress and emotion. Frontiers in Endocrinology. 2011;2:19. doi:10.3389/fendo.2011.00019
8. Li H, Lim L, Roberts LR, et al. Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome. Journal of Biological Chemistry. 2019;294(49):18586–18599. doi:10.1074/jbc.RA119.010950
9. Su J, Hu TT, Zhang Y, Cheng YR, Zhang ZF. Global, regional, and national burden of anxiety disorders during the perimenopause (1990–2021) and projections to 2035. BMC Women’s Health. 2025;25:47. doi:10.1186/s12905-025-03547-z
10. Gold EB, Kravitz HM, Bromberger JT, et al. Does risk for anxiety increase during the menopausal transition? Study of Women’s Health Across the Nation. Menopause. 2013;20(5):488–495. doi:10.1097/gme.0b013e3182730599
11. Chen D, Zhao FG, Xu KY, et al. Role of allopregnanolone-mediated γ-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder. Frontiers in Psychiatry. 2023;14:1140796. doi:10.3389/fpsyt.2023.1140796
12. Morrow AL, Porcu P, Girdler SS, et al. A history of depression in women is associated with an altered GABAergic neuroactive steroid profile. Psychoneuroendocrinology. 2012;37(4):543–553. doi:10.1016/j.psyneuen.2011.08.004
13. Wiley AS, de Wit AE, Athappilly GK, et al. Impact of estradiol variability and progesterone on mood in perimenopausal women with depressive symptoms. Journal of Clinical Endocrinology & Metabolism. 2020;105(3):dgz181. doi:10.1210/clinem/dgz181
14. Rasmusson AM, Liang JJ. Overview of the molecular steps in steroidogenesis of the GABAergic neurosteroids allopregnanolone and pregnanolone. Chronic Stress. 2018;2:2470547018818555. doi:10.1177/2470547018818555
15. Foy MR, Baudry M, Brinton RD, Thompson RF. Estrogen and hippocampal plasticity in rodent models. Journal of Alzheimer’s Disease. 2008;15(3):589–603. PMC:PMC4769981 — oestrogen and glutamatergic transmission, synaptic excitability.
16. Wiley AS, de Wit AE, Athappilly GK, et al. Impact of estradiol variability and progesterone on mood in perimenopausal women with depressive symptoms. Journal of Clinical Endocrinology & Metabolism. 2020;105(3):e642–e650. doi:10.1210/clinem/dgz181 — estradiol variability and serotonergic/dopaminergic mood disruption; depressive symptoms linked to oestradiol fluctuation independent of vasomotor symptoms.
17. Deshpande N, Sathyanarayana Rao TS. Psychological changes at menopause: anxiety, mood swings, and sexual health in the biopsychosocial context. Women’s Health. 2025. doi:10.1177/26318318251324577 — estradiol fluctuations disrupting dopamine, serotonin, and norepinephrine during perimenopause.
18. Baker FC, Lampio L, Saaresranta T, Polo-Kantola P. Sleep and sleep disorders in the menopausal transition. Sleep Medicine Clinics. 2018;13(3):443–456; and associated systematic review: Pien GW, Sammel MD, Freeman EW, et al. Role of ovarian hormones in perimenopausal sleep disturbances. ZORA University of Zurich. 2021. — oestrogen variability and sleep architecture disruption independent of vasomotor symptoms. See also: PubMed 35878624 — associations of oestradiol levels with nocturnal awakenings and sleep continuity in perimenopausal women.
19. Smith SS. Withdrawal properties of a neuroactive steroid: implications for GABAA receptor gene regulation in the brain and anxiety behavior. Steroids. 2002;67(6):519–528. doi:10.1016/S0039-128X(01)00170-2